The VANHEALTHING Cryptofund of Biotech innovations is an absolutely unique investment platform: profits are combined with premier access to cutting-edge biotechnological projects that save and improve human lives.
ICO starts in
Managing partner and board member of USP Capital Ltd. and VANHEALTHING Cryptofund of biotech innovations.
Managing partner and board member of venture capital fund USP Capital Ltd. And VANHEALTHING Cryptofund of biotech innovations.
Managing partner of VANHEALTHING Cryptofund of biotech innovations. Expert in investment and high-tech ecosystems.
CEO and co-founder of biotech company Planexta Inc. Expert in biotech management.
PhD in biophysics, director of the Institute of High Technologies. Leads projects in bio-photonics, oncology, medical lasers and other fields.
PhD in technical sciences, expert in complex mathematical analysis. Author of advanced computational models in biotech projects (for example – reading a person’s biodata and emotional state through a phone camera).
World-class Big Data and computer engineering researcher. Author of Metarhia – a cutting-edge Big Data analytics engine used by Chinese interactive TV channels.
Founder and managing Partner of Sikorsky Challenge
Victoria Ustimenko - Chief PR Officer at the VanHealthing CryptoFund of Biotech Innovations. Portfolio of Victoria counts a number of successfully implemented pr campaigns of 2017 for such brands as SingularityNET, Blackmoon Crypto, WishFinance, Paragon Coin, Sonm as a part of the agency ICO Promo.
Head of R&D and co-founder of Planexta, Inc. Expert in medical research and tech implementation.
Sergey Stirenko is the head of the R&D department of supercomputer calculations, AI and AR/VR of the VANHEALTHING Cryptofund of biotech innovations. Sergey is a high-level specialist in the field of artificial intelligence, virtual and augmented reality, as well as supercomputer calculations.
Improve your life and shape the future!
We provide amazing biotech products that normally take years to reach the public. Don’t wait to increase your life’s span and quality – get access now!
Medical technologies should be affordable and transparent. We believe in a sustainable business model based on social responsibility and earning our clients’ trust.
Invest efficiently into functioning successful projects and early R&D advancements. We offer complete transparency, great profit projections and effective financial management.
Read about us in full detail! VANHEALTHING opens up an entire world of astounding biotechnological projects. We present a comprehensive description of our successful portfolio companies, world-class scientists, professional managers and investment methods.
First angel investment into the Force project.
The USP Capital venture fund is launched.
First successful Kickstarter campaign completed by our portfolio company.
Successful cardio-screening of 22 433 patients in rural areas. The Platform 20k project is born.
Plans for the world’s first psychometer are formulated – a unique device for constant monitoring of an individual’s psycho-emotional state.
The TRL3 experiment for the world’s first one-hand ECG sensor is successfully conducted.
Incorporation of Platform 20k and Planexta Inc.
Start of development on PRECISE – the automated ECG interpretation project.
Start of development on the world’s first sleeveless arterial blood pressure monitor with +-5 mm Hg accuracy.
Creation of the SenceBand TRL6 prototype.
Successful completion of the SenceBand crowdfunding campaign.
SenceBand receives two CES 2017 awards in the biotechnologies and wearable devices categories.
- One of our portfolio companies is chosen for the Vertical accelerator (Finland), considered to be one of the world’s best accelerators in digital health tech.
The TRL4 prototype is created by Planexta Care. This is the world’s first sleeveless arterial blood pressure monitor with +-3 mm Hg accuracy.
- One of our portfolio companies is chosen for the Alchemist accelerator (U.S.A.), considered to be one of the world’s best accelerator programs.
- The digital beta of PRECISE is launched.
Start of clinical trials for PRECISE.
The Fund’s portfolio increases to 12 companies – a major new milestone.
Start of the Fund’s transformation into a cryptocurrency fund.
- Creation of the TRL4 prototype of Pure Purr – a VR-based technology for human nervous system analysis.
- Establishment of SenceTech – the company responsible for implementing Planexta Inc. technologies in the United States and other developed countries.
- The Cryptofund’s development strategy is finalized.
- Publication of a fundamental scientific paper on aging predictor analysis and the dynamic estimation of biological age.
- Development of a unique new algorithm for ECG annotation.
- Establishment of Precise Cardiology Limited, which provides automated ECG interpretation services to healthcare systems.
- The Cryptofund’s portfolio is created.
- The medical version of SenceBand is named among the top 20 remote assistance projects of 2017 by HealthcareTech Outlook.
- Pre-clinical trials of Pure Purr begin.
- SenceTech is chosen as one of the three biotech companies at TechCrunch Disrupt (Berlin).
- SenceTech is selected for the Web Summit PITCH.
The Fund conducts a Roadshow for the purpose of engaging investors and partners for the Cryptofund.
Establishment and registration of the Cryptofund.
Creation of the Cryptofund’s board of directors and investment strategy.
Preparation for the ITO and coordination with regulators for the purpose of issuing tokens.
Establishment of the Cryptofund’s hedge-fund division for the purpose of liquidity management.
Demonstration of successful technological and financial results by the Cryptofund’s portfolio companies.
Launch of our ITO
- Portfolio companies begin investment using gathered funds.
- Launch of the first stage of our A.R.K. infrastructure project, specifically – the initial laboratory construction phase.
payment of dividends to token owners.
Launch of the final stage of the A.R.K. infrastructure project.
Launch of the final stage of the A.R.K. infrastructure project.
Launch of new technological projects within the Cryptofund.
CEO/Co-Founder - SenceTech, Inc (Vanhealthing portfolio company), CCO - Planexta, Inc. Strategic Commercialization Advisor - Vanhealthing. Irene Brinker is a 20+ year veteran sales and marketing leader known for out of the box concept and process creation resulting in high margin ROI for partners and investors. With a diverse background bridging consumer goods, high-value services, and financial investment/sales she brings a well-rounded perspective and trained eye to Vanhealthing.
Chief Promotion Officer of VANHEALTHING fund, founder and CEO of media holding ESM.one, which unites three innovative IT platforms (ESC, Fundy.us and Zeer.tv) in the fields of Big Data analytics, online payments and promotion of e-sports on the global scene. Has experience in managing large teams, as well as promoting media and high-tech projects.
Dr. Greg Colvin
Dr. Colvin was originally trained in neuroscience and cognitive psychology, with a Ph.D. from Cornell University. Since then he has had decades of technical experience inventing algorithms, designing systems, and programming information systems, database servers, and virtual machines. He served for years on the ISO C++ Standards committee, and as Principal Engineer at Oracle Corporation.
Dr. Ben Goertzel
Dr. Ben Goertzel, best known as the father of Artificial General Intelligence, has also been at the forefront of the application of AI to biomedicine and specifically the genomics of longevity, for nearly two decades. He has worked directly with the National Institutes of Health (NIH), one of the world's foremost medical research centers and US Centers for Disease Control and Prevention (CDC) in applying AI towards discovering critical aspects of the genetic basis for Parkinson’s Disease, Chronic Fatigue Syndrome and Alzheimer’s. Dr. Goertzel has published 141 scientific articles and 12 scientific books in the field of AI.
Vanhealthing network token
Register to have an opportunity to buy token.